Innoviva Long Term Debt 2010-2023 | INVA

Innoviva long term debt from 2010 to 2023. Long term debt can be defined as the sum of all long term debt fields.
Innoviva Annual Long Term Debt
(Millions of US $)
2023 $446
2022 $444
2021 $395
2020 $386
2019 $377
2018 $383
2017 $574
2016 $708
2015 $733
2014 $726
2013 $288
2012 $173
2011 $173
2010 $173
2009 $173
Innoviva Quarterly Long Term Debt
(Millions of US $)
2023-12-31 $446
2023-09-30 $446
2023-06-30 $445
2023-03-31 $445
2022-12-31 $444
2022-09-30 $444
2022-06-30 $443
2022-03-31 $443
2021-12-31 $395
2021-09-30 $392
2021-06-30 $390
2021-03-31 $388
2020-12-31 $386
2020-09-30 $383
2020-06-30 $381
2020-03-31 $379
2019-12-31 $377
2019-09-30 $389
2019-06-30 $387
2019-03-31 $385
2018-12-31 $383
2018-09-30 $381
2018-06-30 $487
2018-03-31 $485
2017-12-31 $574
2017-09-30 $578
2017-06-30 $639
2017-03-31 $702
2016-12-31 $708
2016-09-30 $719
2016-06-30 $722
2016-03-31 $735
2015-12-31 $733
2015-09-30 $744
2015-06-30 $738
2015-03-31 $732
2014-12-31 $726
2014-09-30 $705
2014-06-30 $738
2014-03-31 $288
2013-12-31 $288
2013-09-30 $288
2013-06-30 $460
2013-03-31 $460
2012-12-31 $173
2012-09-30 $173
2012-06-30 $173
2012-03-31 $173
2011-12-31 $173
2011-09-30 $173
2011-06-30 $173
2011-03-31 $173
2010-12-31 $173
2010-09-30 $173
2010-06-30 $173
2010-03-31 $173
2009-12-31 $173
2009-09-30 $173
2009-06-30 $173
2009-03-31 $173
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.998B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62